Literature DB >> 12479132

[Clinical and experimental study of treatment of nanmiqing capsule for chronic prostatitis].

Chun-Fu Dai1, Zhi-Zhong Zhang, Xing-Liang Qi, Ming-Xuan Zhang, Yan-Ping Li.   

Abstract

OBJECTIVES: To investigate the clinical effect and therapeutic mechanism of Nanmiqing capsule made of rheum palmatum, leech, astragalus memberanaceus on patients with chronic prostatitis(CP).
METHODS: Seventy-six CP cases were treated with Nanmiqing, while 32 CP cases were treated with Qianliekang as a control. The changes of EPS were observed pre- and post-treatment. The rat model of CP got by Xiaozhiling inducing were treated with Nanmiqing and Qianliekang respectively. The concentration of endothelin, TXB2, 6-keto-PGF1 alpha and SOD, IgG, IgA in plasma were measured pre- and post-treatment, meanwhile, pathological changes of prostate tissues were observed.
RESULTS: The total effective rate was 89.47% in treatment group, which was significantly higher than 71.88% in the control group (P < 0.01). Experimental study for CP rats showed that the Nanmiqing was more effective medicine than Qianliekang (P < 0.01).
CONCLUSIONS: Nanmiqing was an effective medicine for CP. The mechanism of clearing heat and resolving toxin, activating blood and removing stasis and reinforcing Qi in chinese medicine could be the explanation of the useful treatment including three therapentic ways.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12479132

Source DB:  PubMed          Journal:  Zhonghua Nan Ke Xue        ISSN: 1009-3591


  2 in total

1.  The effect of Qianliekang tablets on the clinical efficacy, immune function, and inflammatory factor levels in the prostatic fluid of elderly chronic prostatitis patients.

Authors:  Chao Yang; Jun Yao; Tianping Chen
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

2.  Complementary and alternative medicine for chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Jillian L Capodice; Debra L Bemis; Ralph Buttyan; Steven A Kaplan; Aaron E Katz
Journal:  Evid Based Complement Alternat Med       Date:  2005-10-10       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.